But that doesn't mean that compounded versions of semaglutide and tirzepatide — the active ingredients in the blockbuster drugs Ozempic, Wegovy, Mounjaro, and Zepbound — will become unavailable.

The Food and Drug Administration said in a court filing late Friday that it would allow pharmacists to continue making compounded versions of tirzepatide — the active ingredient in Eli Lilly’s ...

When Lilly’s coupon program ended in the summer of 2023, McCaskill’s health-care provider suggested another option: compounded tirzepatide, a version of the drug that’s not FDA-approved but ...

To understand why compounding pharmacists can make copies of semaglutide (the key ingredient in Ozempic and Wegovy) and tirzepatide (the key ingredient in Mounjaro and Zepbound), you have to ...

If tirzepatide remains off the FDA's drug shortage list, compounding pharmacies must cease the production of these medications on any significant scale, according to gastroenterologist and obesity ...

The shortage of the diabetes and obesity injectable tirzepatide (Mounjaro, Zepbound) has been resolved, the FDA announced Thursday. As a result, compounders will have a grace period of 60 to 90 ...

Demand for popular weight loss drugs such as semaglutide (Wegovy) and tirzepatide (Zepbound) has long outpaced supply, forcing many patients with obesity to visit compounding pharmacies to get ...

When Christina and Jackson Agar used to get a pizza, they'd polish it off the same night. Things are different now that they're both taking an obesity drug. "We recently ordered a pizza and we ate ...

In a reversal, the Food and Drug Administration (FDA) said it will allow some compounding pharmacies to temporarily make their own versions of tirzepatide, the active ingredient in Eli Lilly’s ...

Eli Lilly has filed a lawsuit against four telehealth platforms selling compounded versions of its blockbuster metabolic disorder drug tirzepatide, marking the latest power struggle between weight ...

On October 3, 2024, the US Food and Drug Administration (FDA) revised its shortage categorization of tirzepatide, a glucagon-like peptide 1 (GLP-1) medication, marking the shortage as “resolved ...